A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2014
Price : $35 *
At a glance
- Drugs PHP 201 (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Amakem
- 05 Feb 2014 Updated results of this trial were presented at the Glaucoma 360 New Horizons Forum, according to an Amakem media release.
- 20 Nov 2013 New trial record
- 14 Nov 2013 Top-line results were presented at the Ophthalmology Innovation Summit (OIS) at the 2013 Annual Meeting of the American Academy of Ophthalmology, according to an Amakem media release.